Candidate: Vaccine protecting against COVID-19 variants
Type: Vaccine based on Dyadic’s C1 technology platform
2021 Status: Dyadic said March 22 that it is expanding its partnership with South Korea-based Medytox by agreeing to co-develop C1 manufactured COVID-19 vaccines and/or boosters, for use in immunizing against two or more current and future COVID-19 variants. The value of the partnership has not been disclosed. Investors responded enthusiastically to the news, sending Dyadic shares up 29% to a closing price of $6.87 from $5.33 on March 19.
The companies began working together in July 2020, when Medytox gained access to Dyadic’s C1 expression platform.
“Based on our experience and comparing the C1 technology platform against several other expression platforms such as CHO and insect cells, we believe that the fungi-derived C1 expression system is the most realistic technology to develop and manufacture multi-valent (i.e., tri-valent, and tetra-valent) vaccines, rapidly and affordably, against COVID-19 mutant viruses without the need for a large-scale bioreactor facility,” stated Gi-Hyeok Yang, PhD, Medytox’s senior executive vice president and head of research and development.
COVID-19: 300 Candidates and Counting
To navigate through the >300 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: